edison tv
Metals & Mining
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: OpGen
Edison Investment Research has terminated coverage on OpGen (OPGN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
OpGen — 5 videos in collection
OpGen (Nasdaq CM: OPGN) has announced encouraging top-line data from its Unyvero urinary tract infection (UTI) panel trial.
The Unyvero UTI panel is a diagnostic test designed to detect pathogens and antimicrobial resistance markers related to UTI from native urine specimens without the need for culturing, bringing test times down to less than five hours.
In this video, Edison Group Managing Director, Soo Romanoff and OpGen’s CEO, Oliver Schacht, discuss the significance of the trial data and OpGen’s future plans.
Get access to the very latest content matched to your personal investment style.